Want to see SE:CI full AI Analyst Report?
Top Page
Cell Impact AB
(CI)
Select Model
Select Model
Rating:42Neutral
Price Target:
kr0.03
▼(-58.57% Downside)
Action:Upgraded
Date:09/15/26
The score is primarily held down by weak financial performance—large losses, negative gross profit, declining revenue, and persistent cash burn—despite relatively modest leverage. Technicals also remain bearish with the price well below key moving averages, even though oversold indicators suggest only limited near-term stabilization potential. Valuation provides little support given a negative P/E and no dividend yield data.
Positive Factors
Proprietary hydrogen manufacturing technology
The proprietary high-velocity forming technology gives Cell Impact a defined position in an emerging hydrogen manufacturing niche. If customers scale fuel-cell and electrolyzer production, the technology could support repeatable industrial deployments and strengthen the company’s relevance to that value chain.
Negative Factors
Shrinking revenue and negative gross profit
Declining revenue combined with negative gross profit indicates that Cell Impact is facing both weaker volume and unsustainable unit economics. Unless demand improves and production economics recover, the business may struggle to convert its technology and hydrogen exposure into durable operating profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary hydrogen manufacturing technology
The proprietary high-velocity forming technology gives Cell Impact a defined position in an emerging hydrogen manufacturing niche. If customers scale fuel-cell and electrolyzer production, the technology could support repeatable industrial deployments and strengthen the company’s relevance to that value chain.
Read all positive factors
Cell Impact AB (CI) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr40.61M
Dividend YieldN/A
Average Volume (3M)5.34M
Price to Earnings (P/E)―
Beta (1Y)0.82
Revenue Growth-56.60%
EPS Growth51.95%
CountrySE
Employees25
SectorGeneral
Sector StrengthN/A
IndustryManufacturing - Metal Fabrication
Share Statistics
EPS (TTM)-0.41
Shares Outstanding1,326,965,700
10 Day Avg. Volume8,584,763
30 Day Avg. Volume5,340,984
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.27
Price to Sales (P/S)5.83
P/FCF Ratio-0.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.42
Revenue Forecast (FY)kr17.00M
Cell Impact AB Business Overview & Revenue Model
Company Description
Cell Impact AB (publ) is a Swedish firm that specializes in the global production and distribution of bipolar flow plates, which are crucial components for hydrogen fuel cells. The company's products include plates designed with meticulously preci...
How the Company Makes Money
Cell Impact makes money primarily by selling industrial equipment and manufacturing solutions used to produce metallic bipolar (flow) plates for fuel cells and electrolyzers. Key revenue streams include: (1) sales of forming equipment/production l...
Cell Impact AB Financial Statement Overview
Summary
Income Statement
9
Very Negative
Balance Sheet
42
Neutral
Cash Flow
14
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.12M | 5.57M | 37.33M | 47.26M | 76.81M | 71.35M |
| Gross Profit | -135.36M | -121.42M | 5.42M | 25.45M | 36.94M | 34.88M |
| EBITDA | -49.36M | -55.03M | -66.52M | -97.72M | -86.22M | -68.84M |
| Net Income | -125.35M | -131.98M | -100.43M | -121.40M | -104.22M | -79.85M |
Balance Sheet | ||||||
| Total Assets | 135.93M | 163.37M | 261.25M | 381.93M | 401.51M | 238.72M |
| Cash, Cash Equivalents and Short-Term Investments | 424.00K | 10.86M | 20.39M | 99.89M | 164.67M | 28.56M |
| Total Debt | 13.91M | 32.54M | 30.92M | 42.75M | 44.70M | 19.51M |
| Total Liabilities | 33.79M | 42.34M | 42.16M | 78.56M | 77.17M | 96.10M |
| Stockholders Equity | 102.14M | 121.03M | 219.08M | 303.37M | 324.35M | 142.63M |
Cash Flow | ||||||
| Free Cash Flow | -36.31M | -47.29M | -76.66M | -152.75M | -174.32M | -140.39M |
| Operating Cash Flow | -34.80M | -45.36M | -62.23M | -100.97M | -105.93M | -86.08M |
| Investing Cash Flow | 2.63M | 2.30M | -14.43M | -51.78M | -68.40M | -54.32M |
| Financing Cash Flow | 31.77M | 33.68M | -2.84M | 88.09M | 310.47M | 17.01M |
Cell Impact AB Technical Analysis
Negative
0.07
Price Trends
0.05
Negative
0.07
Negative
0.11
Negative
Market Momentum
>-0.01
Negative
16.44
Positive
29.52
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:CI, the sentiment is Negative. The current price of 0.07 is above the 20-day moving average (MA) of 0.04, above the 50-day MA of 0.05, and below the 200-day MA of 0.11, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 16.44 is Positive, neither overbought nor oversold. The STOCH value of 29.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:CI.
Cell Impact AB Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
49 Neutral | kr375.01M | -29.14 | ― | ― | 54.37% | 52.22% | |
42 Neutral | kr40.61M | -0.07 | ― | ― | -56.60% | 51.95% | |
42 Neutral | kr388.85M | -7.85 | ― | ― | -2.61% | -0.28% | |
41 Neutral | kr218.63M | -1.00 | -303.61% | ― | 51.21% | 42.24% | |
41 Neutral | kr78.11M | -1.89 | ― | ― | ― | 13.53% | |
41 Neutral | kr578.77M | -7.42 | ― | ― | ― | -23.57% |
* General Sector Average
SE:CI
Cell Impact AB
0.03
-0.08
-72.12%
SE:SCIB
SciBase Holding AB
15.90
-15.40
-49.20%
SE:ANNX
Annexin Pharmaceuticals AB
8.82
-18.37
-67.56%
SE:OSSD
OssDsign AB
3.55
-10.69
-75.07%
SE:CLBIO
Corline Biomedical AB
14.35
-4.20
-22.64%
SE:FLUO
FluoGuide A/S
33.80
-5.30
-13.55%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.